nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Goserelin—breast cancer	0.406	1	CrCtD
Degarelix—GNRHR—Goserelin—breast cancer	0.262	1	CbGbCtD
Degarelix—Cetrorelix—Goserelin—breast cancer	0.0788	0.315	CrCrCtD
Degarelix—Ceruletide—Goserelin—breast cancer	0.0681	0.272	CrCrCtD
Degarelix—Nafarelin—Goserelin—breast cancer	0.0541	0.216	CrCrCtD
Degarelix—Gonadorelin—Goserelin—breast cancer	0.0492	0.197	CrCrCtD
Degarelix—GNRHR—GPCR ligand binding—CCL27—breast cancer	9.9e-05	0.00921	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL3—breast cancer	9.9e-05	0.00921	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL20—breast cancer	9.4e-05	0.00874	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EDNRB—breast cancer	9.32e-05	0.00867	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—breast cancer	9.11e-05	0.00847	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—breast cancer	8.38e-05	0.00779	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—AGTR1—breast cancer	8.37e-05	0.00778	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—ITPR1—breast cancer	7.51e-05	0.00698	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—breast cancer	7.48e-05	0.00696	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	7.21e-05	0.0067	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	7.21e-05	0.0067	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL20—breast cancer	7.16e-05	0.00666	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GPER1—breast cancer	7.04e-05	0.00655	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—LPAR1—breast cancer	6.93e-05	0.00645	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	6.9e-05	0.00642	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STARD8—breast cancer	6.9e-05	0.00641	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—NMBR—breast cancer	6.75e-05	0.00628	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—breast cancer	6.71e-05	0.00624	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—breast cancer	6.67e-05	0.0062	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GPER1—breast cancer	6.4e-05	0.00595	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CNR2—breast cancer	6.38e-05	0.00593	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTGER1—breast cancer	6.28e-05	0.00584	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NMBR—breast cancer	6.13e-05	0.0057	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	6.13e-05	0.0057	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	6.13e-05	0.0057	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—WNT1—breast cancer	6e-05	0.00558	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTGER1—breast cancer	5.7e-05	0.0053	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PDE2A—breast cancer	5.6e-05	0.0052	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCL27—breast cancer	5.6e-05	0.0052	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL3—breast cancer	5.6e-05	0.0052	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	5.54e-05	0.00515	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—AGTR2—breast cancer	5.49e-05	0.0051	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL2—breast cancer	5.49e-05	0.0051	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTHLH—breast cancer	5.43e-05	0.00505	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—EDNRB—breast cancer	5.26e-05	0.00489	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—WNT10B—breast cancer	5.21e-05	0.00485	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL27—breast cancer	5.08e-05	0.00473	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL3—breast cancer	5.08e-05	0.00473	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PDE2A—breast cancer	5.08e-05	0.00473	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CALCA—breast cancer	4.78e-05	0.00444	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL12—breast cancer	4.67e-05	0.00434	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCR4—breast cancer	4.67e-05	0.00434	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—AGTR1—breast cancer	4.22e-05	0.00392	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RGS2—breast cancer	4.09e-05	0.0038	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCL20—breast cancer	4.05e-05	0.00376	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCDC88C—breast cancer	3.96e-05	0.00368	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LGR6—breast cancer	3.96e-05	0.00368	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—LPAR1—breast cancer	3.92e-05	0.00364	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GPER1—breast cancer	3.78e-05	0.00351	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SFRP1—breast cancer	3.78e-05	0.00351	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RGS2—breast cancer	3.72e-05	0.00346	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PDE4D—breast cancer	3.7e-05	0.00344	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL20—breast cancer	3.67e-05	0.00342	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	3.65e-05	0.0034	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NMBR—breast cancer	3.62e-05	0.00337	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CNR2—breast cancer	3.61e-05	0.00335	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—LPAR1—breast cancer	3.56e-05	0.00331	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HEYL—breast cancer	3.37e-05	0.00313	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CUL5—breast cancer	3.37e-05	0.00313	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTGER1—breast cancer	3.37e-05	0.00313	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PDE4D—breast cancer	3.36e-05	0.00312	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CNR2—breast cancer	3.27e-05	0.00305	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RSPO3—breast cancer	3.17e-05	0.00294	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AGTR2—breast cancer	3.1e-05	0.00288	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL2—breast cancer	3.1e-05	0.00288	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—WNT10B—breast cancer	3.08e-05	0.00286	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—WWOX—breast cancer	3.08e-05	0.00286	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—WNT1—breast cancer	3.08e-05	0.00286	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTHLH—breast cancer	3.07e-05	0.00285	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDE2A—breast cancer	3e-05	0.00279	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL3—breast cancer	3e-05	0.00279	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL27—breast cancer	3e-05	0.00279	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—INHBB—breast cancer	3e-05	0.00279	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—EDNRB—breast cancer	2.97e-05	0.00276	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BMPR2—breast cancer	2.86e-05	0.00266	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DLL4—breast cancer	2.86e-05	0.00266	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AGTR2—breast cancer	2.82e-05	0.00262	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL2—breast cancer	2.82e-05	0.00262	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTHLH—breast cancer	2.78e-05	0.00259	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDH5—breast cancer	2.75e-05	0.00255	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CALCA—breast cancer	2.7e-05	0.00251	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EDNRB—breast cancer	2.7e-05	0.00251	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SFRP2—breast cancer	2.69e-05	0.0025	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRLR—breast cancer	2.64e-05	0.00246	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL12—breast cancer	2.64e-05	0.00245	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCR4—breast cancer	2.64e-05	0.00245	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	2.63e-05	0.00245	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VCP—breast cancer	2.55e-05	0.00237	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GLI2—breast cancer	2.55e-05	0.00237	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	2.54e-05	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LEPR—breast cancer	2.51e-05	0.00234	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	2.51e-05	0.00233	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CALCA—breast cancer	2.45e-05	0.00228	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—breast cancer	2.43e-05	0.00226	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCR4—breast cancer	2.39e-05	0.00223	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL12—breast cancer	2.39e-05	0.00223	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AGTR1—breast cancer	2.38e-05	0.00222	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	2.37e-05	0.0022	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ARHGDIA—breast cancer	2.33e-05	0.00217	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FST—breast cancer	2.28e-05	0.00212	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HEY2—breast cancer	2.25e-05	0.00209	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RPS6KB2—breast cancer	2.22e-05	0.00206	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RGS2—breast cancer	2.2e-05	0.00204	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	2.18e-05	0.00202	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL20—breast cancer	2.17e-05	0.00202	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AGTR1—breast cancer	2.17e-05	0.00201	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ITPR1—breast cancer	2.14e-05	0.00199	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TLE3—breast cancer	2.1e-05	0.00195	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LPAR1—breast cancer	2.1e-05	0.00195	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HEY1—breast cancer	2.08e-05	0.00193	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DLL1—breast cancer	2.04e-05	0.0019	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	2.01e-05	0.00187	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIST1H2BK—breast cancer	2e-05	0.00186	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIST1H2BC—breast cancer	2e-05	0.00186	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDE4D—breast cancer	1.99e-05	0.00185	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GRB7—breast cancer	1.99e-05	0.00185	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CSF2—breast cancer	1.98e-05	0.00184	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TAB2—breast cancer	1.95e-05	0.00181	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ITPR1—breast cancer	1.94e-05	0.00181	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CNR2—breast cancer	1.93e-05	0.0018	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—breast cancer	1.93e-05	0.0018	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MMP3—breast cancer	1.93e-05	0.00179	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	1.93e-05	0.00179	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DKK1—breast cancer	1.89e-05	0.00176	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFC—breast cancer	1.87e-05	0.00174	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JAG2—breast cancer	1.85e-05	0.00172	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—WNT1—breast cancer	1.82e-05	0.00169	CbGpPWpGaD
Degarelix—Nervous system disorder—Docetaxel—breast cancer	1.82e-05	0.000254	CcSEcCtD
Degarelix—Pruritus—Fluorouracil—breast cancer	1.82e-05	0.000254	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PLA2G4A—breast cancer	1.81e-05	0.00169	CbGpPWpGaD
Degarelix—Feeling abnormal—Paclitaxel—breast cancer	1.8e-05	0.000252	CcSEcCtD
Degarelix—Skin disorder—Docetaxel—breast cancer	1.8e-05	0.000251	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CSF2—breast cancer	1.79e-05	0.00167	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Paclitaxel—breast cancer	1.79e-05	0.00025	CcSEcCtD
Degarelix—Diarrhoea—Gemcitabine—breast cancer	1.79e-05	0.00025	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—breast cancer	1.78e-05	0.000249	CcSEcCtD
Degarelix—Dizziness—Irinotecan—breast cancer	1.77e-05	0.000248	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—breast cancer	1.76e-05	0.000246	CcSEcCtD
Degarelix—Nervous system disorder—Capecitabine—breast cancer	1.76e-05	0.000246	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—breast cancer	1.76e-05	0.000245	CcSEcCtD
Degarelix—Diarrhoea—Fluorouracil—breast cancer	1.76e-05	0.000245	CcSEcCtD
Degarelix—Hypoaesthesia—Epirubicin—breast cancer	1.75e-05	0.000244	CcSEcCtD
Degarelix—Cardiac disorder—Methotrexate—breast cancer	1.75e-05	0.000244	CcSEcCtD
Degarelix—Skin disorder—Capecitabine—breast cancer	1.74e-05	0.000243	CcSEcCtD
Degarelix—Urinary tract disorder—Epirubicin—breast cancer	1.74e-05	0.000243	CcSEcCtD
Degarelix—Urticaria—Paclitaxel—breast cancer	1.74e-05	0.000243	CcSEcCtD
Degarelix—Hyperhidrosis—Capecitabine—breast cancer	1.74e-05	0.000242	CcSEcCtD
Degarelix—Oedema peripheral—Epirubicin—breast cancer	1.73e-05	0.000242	CcSEcCtD
Degarelix—Hypotension—Docetaxel—breast cancer	1.73e-05	0.000242	CcSEcCtD
Degarelix—Body temperature increased—Paclitaxel—breast cancer	1.73e-05	0.000241	CcSEcCtD
Degarelix—Abdominal pain—Paclitaxel—breast cancer	1.73e-05	0.000241	CcSEcCtD
Degarelix—Urethral disorder—Epirubicin—breast cancer	1.73e-05	0.000241	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH4—breast cancer	1.72e-05	0.0016	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Doxorubicin—breast cancer	1.72e-05	0.00024	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GZMB—breast cancer	1.71e-05	0.00159	CbGpPWpGaD
Degarelix—Angiopathy—Methotrexate—breast cancer	1.71e-05	0.000238	CcSEcCtD
Degarelix—Vomiting—Mitoxantrone—breast cancer	1.71e-05	0.000238	CcSEcCtD
Degarelix—Vomiting—Irinotecan—breast cancer	1.71e-05	0.000238	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—breast cancer	1.7e-05	0.000237	CcSEcCtD
Degarelix—Dizziness—Fluorouracil—breast cancer	1.7e-05	0.000237	CcSEcCtD
Degarelix—Mediastinal disorder—Methotrexate—breast cancer	1.7e-05	0.000237	CcSEcCtD
Degarelix—Rash—Mitoxantrone—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Rash—Irinotecan—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Dermatitis—Mitoxantrone—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Dermatitis—Irinotecan—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Docetaxel—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Chills—Methotrexate—breast cancer	1.69e-05	0.000236	CcSEcCtD
Degarelix—Headache—Irinotecan—breast cancer	1.68e-05	0.000235	CcSEcCtD
Degarelix—Headache—Mitoxantrone—breast cancer	1.68e-05	0.000235	CcSEcCtD
Degarelix—Hypotension—Capecitabine—breast cancer	1.68e-05	0.000234	CcSEcCtD
Degarelix—Insomnia—Docetaxel—breast cancer	1.68e-05	0.000234	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CXCL2—breast cancer	1.66e-05	0.00155	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGTR2—breast cancer	1.66e-05	0.00155	CbGpPWpGaD
Degarelix—Alopecia—Methotrexate—breast cancer	1.66e-05	0.000232	CcSEcCtD
Degarelix—Vomiting—Gemcitabine—breast cancer	1.66e-05	0.000232	CcSEcCtD
Degarelix—Dyspnoea—Docetaxel—breast cancer	1.65e-05	0.000231	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—breast cancer	1.65e-05	0.00023	CcSEcCtD
Degarelix—Rash—Gemcitabine—breast cancer	1.65e-05	0.00023	CcSEcCtD
Degarelix—Dermatitis—Gemcitabine—breast cancer	1.65e-05	0.00023	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—breast cancer	1.65e-05	0.00023	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTHLH—breast cancer	1.64e-05	0.00153	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BMP2—breast cancer	1.64e-05	0.00153	CbGpPWpGaD
Degarelix—Malnutrition—Methotrexate—breast cancer	1.64e-05	0.000229	CcSEcCtD
Degarelix—Erythema—Methotrexate—breast cancer	1.64e-05	0.000229	CcSEcCtD
Degarelix—Headache—Gemcitabine—breast cancer	1.64e-05	0.000228	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Capecitabine—breast cancer	1.64e-05	0.000228	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—breast cancer	1.63e-05	0.000228	CcSEcCtD
Degarelix—Vomiting—Fluorouracil—breast cancer	1.63e-05	0.000228	CcSEcCtD
Degarelix—Insomnia—Capecitabine—breast cancer	1.62e-05	0.000227	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—breast cancer	1.62e-05	0.000226	CcSEcCtD
Degarelix—Rash—Fluorouracil—breast cancer	1.62e-05	0.000226	CcSEcCtD
Degarelix—Dermatitis—Fluorouracil—breast cancer	1.62e-05	0.000226	CcSEcCtD
Degarelix—Decreased appetite—Docetaxel—breast cancer	1.61e-05	0.000225	CcSEcCtD
Degarelix—Hypersensitivity—Paclitaxel—breast cancer	1.61e-05	0.000225	CcSEcCtD
Degarelix—Headache—Fluorouracil—breast cancer	1.61e-05	0.000225	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—breast cancer	1.61e-05	0.000225	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—breast cancer	1.6e-05	0.000224	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—breast cancer	1.6e-05	0.000223	CcSEcCtD
Degarelix—Dyspnoea—Capecitabine—breast cancer	1.6e-05	0.000223	CcSEcCtD
Degarelix—Fatigue—Docetaxel—breast cancer	1.6e-05	0.000223	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—breast cancer	1.6e-05	0.000223	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—breast cancer	1.6e-05	0.000223	CcSEcCtD
Degarelix—Nausea—Irinotecan—breast cancer	1.59e-05	0.000222	CcSEcCtD
Degarelix—Nausea—Mitoxantrone—breast cancer	1.59e-05	0.000222	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—EDNRB—breast cancer	1.59e-05	0.00148	CbGpPWpGaD
Degarelix—Immune system disorder—Epirubicin—breast cancer	1.59e-05	0.000222	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—breast cancer	1.59e-05	0.000221	CcSEcCtD
Degarelix—Pain—Docetaxel—breast cancer	1.59e-05	0.000221	CcSEcCtD
Degarelix—Constipation—Docetaxel—breast cancer	1.59e-05	0.000221	CcSEcCtD
Degarelix—Back pain—Methotrexate—breast cancer	1.58e-05	0.000221	CcSEcCtD
Degarelix—Chills—Epirubicin—breast cancer	1.58e-05	0.00022	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PGR—breast cancer	1.58e-05	0.00147	CbGpPWpGaD
Degarelix—Arrhythmia—Epirubicin—breast cancer	1.57e-05	0.000219	CcSEcCtD
Degarelix—Asthenia—Paclitaxel—breast cancer	1.57e-05	0.000219	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—THBS1—breast cancer	1.57e-05	0.00146	CbGpPWpGaD
Degarelix—Decreased appetite—Capecitabine—breast cancer	1.56e-05	0.000218	CcSEcCtD
Degarelix—Alopecia—Epirubicin—breast cancer	1.56e-05	0.000217	CcSEcCtD
Degarelix—Nausea—Gemcitabine—breast cancer	1.55e-05	0.000217	CcSEcCtD
Degarelix—Gastrointestinal disorder—Capecitabine—breast cancer	1.55e-05	0.000216	CcSEcCtD
Degarelix—Fatigue—Capecitabine—breast cancer	1.55e-05	0.000216	CcSEcCtD
Degarelix—Pruritus—Paclitaxel—breast cancer	1.55e-05	0.000216	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—breast cancer	1.54e-05	0.000215	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—breast cancer	1.54e-05	0.000215	CcSEcCtD
Degarelix—Constipation—Capecitabine—breast cancer	1.54e-05	0.000214	CcSEcCtD
Degarelix—Pain—Capecitabine—breast cancer	1.54e-05	0.000214	CcSEcCtD
Degarelix—Erythema—Epirubicin—breast cancer	1.53e-05	0.000214	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—breast cancer	1.53e-05	0.000214	CcSEcCtD
Degarelix—Feeling abnormal—Docetaxel—breast cancer	1.53e-05	0.000213	CcSEcCtD
Degarelix—Nausea—Fluorouracil—breast cancer	1.53e-05	0.000213	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—breast cancer	1.52e-05	0.000212	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—breast cancer	1.52e-05	0.000212	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—breast cancer	1.52e-05	0.000212	CcSEcCtD
Degarelix—Anaemia—Methotrexate—breast cancer	1.51e-05	0.000211	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—breast cancer	1.51e-05	0.000211	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FLT1—breast cancer	1.5e-05	0.00139	CbGpPWpGaD
Degarelix—Diarrhoea—Paclitaxel—breast cancer	1.5e-05	0.000209	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF3—breast cancer	1.49e-05	0.00139	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SQSTM1—breast cancer	1.49e-05	0.00139	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—breast cancer	1.48e-05	0.00138	CbGpPWpGaD
Degarelix—Back pain—Epirubicin—breast cancer	1.48e-05	0.000207	CcSEcCtD
Degarelix—Feeling abnormal—Capecitabine—breast cancer	1.48e-05	0.000206	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—breast cancer	1.48e-05	0.000206	CcSEcCtD
Degarelix—Malaise—Methotrexate—breast cancer	1.48e-05	0.000206	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—breast cancer	1.47e-05	0.000206	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—JAG1—breast cancer	1.47e-05	0.00137	CbGpPWpGaD
Degarelix—Immune system disorder—Doxorubicin—breast cancer	1.47e-05	0.000205	CcSEcCtD
Degarelix—Gastrointestinal pain—Capecitabine—breast cancer	1.47e-05	0.000205	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—breast cancer	1.47e-05	0.000205	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH3—breast cancer	1.47e-05	0.00136	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PARP1—breast cancer	1.47e-05	0.00136	CbGpPWpGaD
Degarelix—Abdominal pain—Docetaxel—breast cancer	1.47e-05	0.000205	CcSEcCtD
Degarelix—Body temperature increased—Docetaxel—breast cancer	1.47e-05	0.000205	CcSEcCtD
Degarelix—Chills—Doxorubicin—breast cancer	1.46e-05	0.000204	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—breast cancer	1.46e-05	0.000203	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CALCA—breast cancer	1.45e-05	0.00135	CbGpPWpGaD
Degarelix—Dizziness—Paclitaxel—breast cancer	1.45e-05	0.000202	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—breast cancer	1.44e-05	0.000202	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—breast cancer	1.44e-05	0.000201	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—RPS6—breast cancer	1.43e-05	0.00133	CbGpPWpGaD
Degarelix—Mental disorder—Doxorubicin—breast cancer	1.43e-05	0.000199	CcSEcCtD
Degarelix—Urticaria—Capecitabine—breast cancer	1.43e-05	0.000199	CcSEcCtD
Degarelix—Ill-defined disorder—Epirubicin—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF4—breast cancer	1.42e-05	0.00132	CbGpPWpGaD
Degarelix—Abdominal pain—Capecitabine—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—Body temperature increased—Capecitabine—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—Erythema—Doxorubicin—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—Anaemia—Epirubicin—breast cancer	1.42e-05	0.000198	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CXCL12—breast cancer	1.41e-05	0.00132	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCR4—breast cancer	1.41e-05	0.00132	CbGpPWpGaD
Degarelix—Arthralgia—Methotrexate—breast cancer	1.39e-05	0.000195	CcSEcCtD
Degarelix—Vomiting—Paclitaxel—breast cancer	1.39e-05	0.000194	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PAK1—breast cancer	1.39e-05	0.00129	CbGpPWpGaD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.38e-05	0.000193	CcSEcCtD
Degarelix—Malaise—Epirubicin—breast cancer	1.38e-05	0.000193	CcSEcCtD
Degarelix—Rash—Paclitaxel—breast cancer	1.38e-05	0.000193	CcSEcCtD
Degarelix—Dermatitis—Paclitaxel—breast cancer	1.38e-05	0.000192	CcSEcCtD
Degarelix—Discomfort—Methotrexate—breast cancer	1.38e-05	0.000192	CcSEcCtD
Degarelix—Back pain—Doxorubicin—breast cancer	1.37e-05	0.000191	CcSEcCtD
Degarelix—Headache—Paclitaxel—breast cancer	1.37e-05	0.000191	CcSEcCtD
Degarelix—Hypersensitivity—Docetaxel—breast cancer	1.37e-05	0.000191	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TCF7L2—breast cancer	1.36e-05	0.00127	CbGpPWpGaD
Degarelix—Muscle spasms—Doxorubicin—breast cancer	1.36e-05	0.00019	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—AKT2—breast cancer	1.36e-05	0.00126	CbGpPWpGaD
Degarelix—Palpitations—Epirubicin—breast cancer	1.35e-05	0.000189	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—breast cancer	1.35e-05	0.00125	CbGpPWpGaD
Degarelix—Anaphylactic shock—Methotrexate—breast cancer	1.34e-05	0.000187	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—breast cancer	1.34e-05	0.000187	CcSEcCtD
Degarelix—Asthenia—Docetaxel—breast cancer	1.33e-05	0.000186	CcSEcCtD
Degarelix—Hypertension—Epirubicin—breast cancer	1.32e-05	0.000185	CcSEcCtD
Degarelix—Hypersensitivity—Capecitabine—breast cancer	1.32e-05	0.000185	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—breast cancer	1.32e-05	0.000184	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH2—breast cancer	1.32e-05	0.00122	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSP90AA1—breast cancer	1.32e-05	0.00122	CbGpPWpGaD
Degarelix—Pruritus—Docetaxel—breast cancer	1.31e-05	0.000183	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—breast cancer	1.31e-05	0.000183	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—breast cancer	1.31e-05	0.000183	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—breast cancer	1.3e-05	0.000182	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—breast cancer	1.3e-05	0.00121	CbGpPWpGaD
Degarelix—Nausea—Paclitaxel—breast cancer	1.3e-05	0.000181	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—breast cancer	1.3e-05	0.000181	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.3e-05	0.000181	CcSEcCtD
Degarelix—Hyperhidrosis—Methotrexate—breast cancer	1.29e-05	0.00018	CcSEcCtD
Degarelix—Discomfort—Epirubicin—breast cancer	1.29e-05	0.00018	CcSEcCtD
Degarelix—Asthenia—Capecitabine—breast cancer	1.29e-05	0.00018	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—AGTR1—breast cancer	1.28e-05	0.00119	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRL—breast cancer	1.28e-05	0.00119	CbGpPWpGaD
Degarelix—Malaise—Doxorubicin—breast cancer	1.28e-05	0.000178	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—breast cancer	1.28e-05	0.000178	CcSEcCtD
Degarelix—Pruritus—Capecitabine—breast cancer	1.27e-05	0.000177	CcSEcCtD
Degarelix—Diarrhoea—Docetaxel—breast cancer	1.27e-05	0.000177	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ADAM10—breast cancer	1.26e-05	0.00117	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STK11—breast cancer	1.26e-05	0.00117	CbGpPWpGaD
Degarelix—Palpitations—Doxorubicin—breast cancer	1.25e-05	0.000175	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—breast cancer	1.25e-05	0.000175	CcSEcCtD
Degarelix—Hypotension—Methotrexate—breast cancer	1.25e-05	0.000174	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PLG—breast cancer	1.25e-05	0.00116	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT2—breast cancer	1.23e-05	0.00115	CbGpPWpGaD
Degarelix—Diarrhoea—Capecitabine—breast cancer	1.23e-05	0.000171	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF10—breast cancer	1.23e-05	0.00114	CbGpPWpGaD
Degarelix—Nervous system disorder—Epirubicin—breast cancer	1.23e-05	0.000171	CcSEcCtD
Degarelix—Dizziness—Docetaxel—breast cancer	1.23e-05	0.000171	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—breast cancer	1.22e-05	0.000171	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—breast cancer	1.22e-05	0.00017	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—breast cancer	1.21e-05	0.00017	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—breast cancer	1.21e-05	0.000169	CcSEcCtD
Degarelix—Insomnia—Methotrexate—breast cancer	1.21e-05	0.000169	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—breast cancer	1.21e-05	0.000168	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.2e-05	0.000167	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—breast cancer	1.19e-05	0.000166	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—breast cancer	1.19e-05	0.000166	CcSEcCtD
Degarelix—Dizziness—Capecitabine—breast cancer	1.19e-05	0.000166	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—breast cancer	1.18e-05	0.0011	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFA—breast cancer	1.18e-05	0.0011	CbGpPWpGaD
Degarelix—Dry mouth—Doxorubicin—breast cancer	1.18e-05	0.000165	CcSEcCtD
Degarelix—Vomiting—Docetaxel—breast cancer	1.18e-05	0.000165	CcSEcCtD
Degarelix—Rash—Docetaxel—breast cancer	1.17e-05	0.000163	CcSEcCtD
Degarelix—Hypotension—Epirubicin—breast cancer	1.17e-05	0.000163	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—breast cancer	1.17e-05	0.000163	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TGFBR2—breast cancer	1.17e-05	0.00108	CbGpPWpGaD
Degarelix—Decreased appetite—Methotrexate—breast cancer	1.16e-05	0.000162	CcSEcCtD
Degarelix—Headache—Docetaxel—breast cancer	1.16e-05	0.000162	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—breast cancer	1.16e-05	0.000162	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—breast cancer	1.15e-05	0.000161	CcSEcCtD
Degarelix—Fatigue—Methotrexate—breast cancer	1.15e-05	0.000161	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ITPR1—breast cancer	1.15e-05	0.00107	CbGpPWpGaD
Degarelix—Pain—Methotrexate—breast cancer	1.14e-05	0.00016	CcSEcCtD
Degarelix—Vomiting—Capecitabine—breast cancer	1.14e-05	0.000159	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ERBB4—breast cancer	1.14e-05	0.00106	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP3—breast cancer	1.14e-05	0.00106	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT5A—breast cancer	1.14e-05	0.00106	CbGpPWpGaD
Degarelix—Musculoskeletal discomfort—Epirubicin—breast cancer	1.14e-05	0.000159	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—breast cancer	1.14e-05	0.00106	CbGpPWpGaD
Degarelix—Nervous system disorder—Doxorubicin—breast cancer	1.13e-05	0.000158	CcSEcCtD
Degarelix—Rash—Capecitabine—breast cancer	1.13e-05	0.000158	CcSEcCtD
Degarelix—Insomnia—Epirubicin—breast cancer	1.13e-05	0.000158	CcSEcCtD
Degarelix—Dermatitis—Capecitabine—breast cancer	1.13e-05	0.000158	CcSEcCtD
Degarelix—Headache—Capecitabine—breast cancer	1.12e-05	0.000157	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—breast cancer	1.12e-05	0.000157	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—breast cancer	1.12e-05	0.000156	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—breast cancer	1.11e-05	0.000156	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SMAD4—breast cancer	1.1e-05	0.00103	CbGpPWpGaD
Degarelix—Nausea—Docetaxel—breast cancer	1.1e-05	0.000154	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—breast cancer	1.1e-05	0.000154	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IGF1R—breast cancer	1.1e-05	0.00102	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Methotrexate—breast cancer	1.09e-05	0.000153	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—breast cancer	1.09e-05	0.00102	CbGpPWpGaD
Degarelix—Decreased appetite—Epirubicin—breast cancer	1.09e-05	0.000152	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—breast cancer	1.08e-05	0.000151	CcSEcCtD
Degarelix—Gastrointestinal disorder—Epirubicin—breast cancer	1.08e-05	0.000151	CcSEcCtD
Degarelix—Fatigue—Epirubicin—breast cancer	1.08e-05	0.00015	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HES1—breast cancer	1.08e-05	0.001	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NCOR1—breast cancer	1.07e-05	0.000997	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PLA2G4A—breast cancer	1.07e-05	0.000997	CbGpPWpGaD
Degarelix—Pain—Epirubicin—breast cancer	1.07e-05	0.000149	CcSEcCtD
Degarelix—Constipation—Epirubicin—breast cancer	1.07e-05	0.000149	CcSEcCtD
Degarelix—Nausea—Capecitabine—breast cancer	1.07e-05	0.000149	CcSEcCtD
Degarelix—Urticaria—Methotrexate—breast cancer	1.06e-05	0.000148	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF1—breast cancer	1.06e-05	0.000986	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CSF2—breast cancer	1.06e-05	0.000986	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RAF1—breast cancer	1.06e-05	0.000983	CbGpPWpGaD
Degarelix—Body temperature increased—Methotrexate—breast cancer	1.06e-05	0.000147	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—breast cancer	1.06e-05	0.000147	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.05e-05	0.000147	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NRG1—breast cancer	1.05e-05	0.000978	CbGpPWpGaD
Degarelix—Insomnia—Doxorubicin—breast cancer	1.05e-05	0.000146	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—H2AFX—breast cancer	1.04e-05	0.000971	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2—breast cancer	1.04e-05	0.000971	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—E2F1—breast cancer	1.04e-05	0.000965	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—breast cancer	1.03e-05	0.00096	CbGpPWpGaD
Degarelix—Dyspnoea—Doxorubicin—breast cancer	1.03e-05	0.000144	CcSEcCtD
Degarelix—Feeling abnormal—Epirubicin—breast cancer	1.03e-05	0.000144	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—breast cancer	1.02e-05	0.000143	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—breast cancer	1.01e-05	0.00014	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—breast cancer	9.99e-06	0.000139	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—breast cancer	9.98e-06	0.000139	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SPP1—breast cancer	9.97e-06	0.000927	CbGpPWpGaD
Degarelix—Urticaria—Epirubicin—breast cancer	9.93e-06	0.000139	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—breast cancer	9.92e-06	0.000923	CbGpPWpGaD
Degarelix—Constipation—Doxorubicin—breast cancer	9.9e-06	0.000138	CcSEcCtD
Degarelix—Pain—Doxorubicin—breast cancer	9.9e-06	0.000138	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—breast cancer	9.89e-06	0.000138	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—breast cancer	9.89e-06	0.000138	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ERBB3—breast cancer	9.86e-06	0.000917	CbGpPWpGaD
Degarelix—Hypersensitivity—Methotrexate—breast cancer	9.85e-06	0.000137	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGFR2—breast cancer	9.84e-06	0.000915	CbGpPWpGaD
Degarelix—Asthenia—Methotrexate—breast cancer	9.59e-06	0.000134	CcSEcCtD
Degarelix—Feeling abnormal—Doxorubicin—breast cancer	9.54e-06	0.000133	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—IL2—breast cancer	9.48e-06	0.000882	CbGpPWpGaD
Degarelix—Gastrointestinal pain—Doxorubicin—breast cancer	9.46e-06	0.000132	CcSEcCtD
Degarelix—Pruritus—Methotrexate—breast cancer	9.45e-06	0.000132	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TERT—breast cancer	9.45e-06	0.000879	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—breast cancer	9.21e-06	0.000129	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—breast cancer	9.19e-06	0.000128	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGFR1—breast cancer	9.17e-06	0.000853	CbGpPWpGaD
Degarelix—Body temperature increased—Doxorubicin—breast cancer	9.15e-06	0.000128	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—breast cancer	9.15e-06	0.000128	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—breast cancer	9.14e-06	0.000128	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HIF1A—breast cancer	9.04e-06	0.00084	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—breast cancer	8.97e-06	0.000125	CcSEcCtD
Degarelix—Pruritus—Epirubicin—breast cancer	8.85e-06	0.000124	CcSEcCtD
Degarelix—Dizziness—Methotrexate—breast cancer	8.84e-06	0.000123	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—LEP—breast cancer	8.82e-06	0.00082	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CAV1—breast cancer	8.74e-06	0.000813	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KDR—breast cancer	8.64e-06	0.000803	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—breast cancer	8.56e-06	0.000119	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—breast cancer	8.53e-06	0.000119	CcSEcCtD
Degarelix—Vomiting—Methotrexate—breast cancer	8.5e-06	0.000119	CcSEcCtD
Degarelix—Rash—Methotrexate—breast cancer	8.43e-06	0.000118	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ESR1—breast cancer	8.42e-06	0.000783	CbGpPWpGaD
Degarelix—Dermatitis—Methotrexate—breast cancer	8.42e-06	0.000118	CcSEcCtD
Degarelix—Headache—Methotrexate—breast cancer	8.37e-06	0.000117	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FN1—breast cancer	8.32e-06	0.000773	CbGpPWpGaD
Degarelix—Asthenia—Doxorubicin—breast cancer	8.3e-06	0.000116	CcSEcCtD
Degarelix—Dizziness—Epirubicin—breast cancer	8.27e-06	0.000115	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NFKBIA—breast cancer	8.22e-06	0.000764	CbGpPWpGaD
Degarelix—Pruritus—Doxorubicin—breast cancer	8.19e-06	0.000114	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH1—breast cancer	8.14e-06	0.000757	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KIT—breast cancer	7.96e-06	0.00074	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APC—breast cancer	7.96e-06	0.00074	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—breast cancer	7.96e-06	0.00074	CbGpPWpGaD
Degarelix—Vomiting—Epirubicin—breast cancer	7.95e-06	0.000111	CcSEcCtD
Degarelix—Nausea—Methotrexate—breast cancer	7.94e-06	0.000111	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—breast cancer	7.92e-06	0.000111	CcSEcCtD
Degarelix—Rash—Epirubicin—breast cancer	7.89e-06	0.00011	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—breast cancer	7.88e-06	0.00011	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—EGF—breast cancer	7.87e-06	0.000732	CbGpPWpGaD
Degarelix—Headache—Epirubicin—breast cancer	7.83e-06	0.000109	CcSEcCtD
Degarelix—Dizziness—Doxorubicin—breast cancer	7.65e-06	0.000107	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—breast cancer	7.62e-06	0.000709	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BRAF—breast cancer	7.48e-06	0.000696	CbGpPWpGaD
Degarelix—Nausea—Epirubicin—breast cancer	7.43e-06	0.000104	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—breast cancer	7.36e-06	0.000103	CcSEcCtD
Degarelix—Rash—Doxorubicin—breast cancer	7.3e-06	0.000102	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—breast cancer	7.29e-06	0.000102	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IGF1—breast cancer	7.29e-06	0.000678	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT2—breast cancer	7.28e-06	0.000677	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EGFR—breast cancer	7.25e-06	0.000674	CbGpPWpGaD
Degarelix—Headache—Doxorubicin—breast cancer	7.25e-06	0.000101	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—breast cancer	7e-06	0.000651	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—breast cancer	6.93e-06	0.000645	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SERPINE1—breast cancer	6.92e-06	0.000644	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—breast cancer	6.87e-06	9.59e-05	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—KRAS—breast cancer	6.85e-06	0.000637	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOS3—breast cancer	6.61e-06	0.000614	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—breast cancer	6.29e-06	0.000585	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MDM2—breast cancer	6.27e-06	0.000583	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RAF1—breast cancer	6.25e-06	0.000581	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RELA—breast cancer	6.22e-06	0.000578	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB2—breast cancer	6.18e-06	0.000575	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—breast cancer	6.1e-06	0.000567	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MTOR—breast cancer	6.1e-06	0.000567	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—breast cancer	5.86e-06	0.000545	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—breast cancer	5.82e-06	0.000541	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1B—breast cancer	5.72e-06	0.000532	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—breast cancer	5.66e-06	0.000527	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—breast cancer	5.61e-06	0.000522	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL2—breast cancer	5.6e-06	0.000521	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—breast cancer	5.57e-06	0.000518	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—breast cancer	5.46e-06	0.000508	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUN—breast cancer	5.45e-06	0.000507	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTNNB1—breast cancer	5.41e-06	0.000503	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—breast cancer	5.3e-06	0.000493	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—breast cancer	5.28e-06	0.000491	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—breast cancer	5.27e-06	0.00049	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK8—breast cancer	5.16e-06	0.000479	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—breast cancer	5.14e-06	0.000478	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SRC—breast cancer	4.89e-06	0.000454	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—breast cancer	4.76e-06	0.000443	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—breast cancer	4.71e-06	0.000438	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—breast cancer	4.5e-06	0.000419	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—breast cancer	4.38e-06	0.000407	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFB1—breast cancer	4.37e-06	0.000406	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—breast cancer	4.28e-06	0.000398	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—breast cancer	4.05e-06	0.000376	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—breast cancer	3.72e-06	0.000346	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—breast cancer	3.6e-06	0.000334	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—breast cancer	3.44e-06	0.00032	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—breast cancer	3.29e-06	0.000306	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—breast cancer	3.04e-06	0.000282	CbGpPWpGaD
